Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
Tenax Therapeutics (NASDAQ: TENX) will present at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston from November 10-12, 2025. The company's presentation is a fireside chat on November 10, 2025 at 4:00 p.m. ET, featuring Chris Giordano, President & Chief Executive Officer, and Stuart Rich, M.D., Chief Medical Officer. A live webcast and archived replay will be available on the company's investor relations webpage.
Tenax Therapeutics (NASDAQ: TENX) parteciperà alla Guggenheim 2nd Annual Healthcare Innovation Conference a Boston dal 10 al 12 novembre 2025. La presentazione dell'azienda è una chiacchierata informale davanti al caminetto il 10 novembre 2025 alle 16:00 ora ET, con Chris Giordano, Presidente e Amministratore Delegato, e Stuart Rich, M.D., Direttore Medico. Una trasmissione in diretta e la riproduzione archiviata saranno disponibili sulla pagina delle relazioni con gli investitori dell'azienda.
Tenax Therapeutics (NASDAQ: TENX) presentará en la Conferencia Guggenheim de Innovación en la Atención Médica, 2.ª edición en Boston desde el 10 al 12 de noviembre de 2025. La presentación de la empresa es una charla junto a la chimenea el 10 de noviembre de 2025 a las 4:00 p.m. hora del Este, con Chris Giordano, Presidente y Director Ejecutivo, y Stuart Rich, M.D., Director Médico. Se dispondrá de una transmisión en vivo y una reproducción archivada en la página de relaciones con inversionistas de la empresa.
Tenax Therapeutics (NASDAQ: TENX)가 보스턴에서 열리는 Guggenheim 2nd Annual Healthcare Innovation Conference에 발표합니다. 행사 기간은 2025년 11월 10-12일입니다. 회사의 발표는 편안한 대담("파이어사이드 채팅") 형식으로 2025년 11월 10일 오후 4:00 EST에 진행되며, Chris Giordano 사장 겸 최고경영자와 Stuart Rich, M.D., 최고의료책임자가 함께합니다. 라이브 생중계 및 아카이브 재방송은 회사의 투자자 관계 웹페이지에서 이용 가능합니다.
Tenax Therapeutics (NASDAQ: TENX) sera présent à la Guggenheim 2nd Annual Healthcare Innovation Conference à Boston du 10 au 12 novembre 2025. La présentation de l'entreprise est une talk-show informelle au coin du feu le 10 novembre 2025 à 16h00, heure de l'Est, avec Chris Giordano, Président et Directeur général, et Stuart Rich, M.D., Directeur médical. Une transmission en direct et une rediffusion archivisée seront disponibles sur la page des relations investisseurs de l'entreprise.
Tenax Therapeutics (NASDAQ: TENX) wird am Guggenheim 2nd Annual Healthcare Innovation Conference in Boston vom 10. bis 12. November 2025 präsentieren. Die Präsentation des Unternehmens ist ein Kamin-Gespräch am 10. November 2025 um 16:00 Uhr ET, mit Chris Giordano, Präsident und Chief Executive Officer, und Stuart Rich, M.D., Chief Medical Officer. Eine Live-Übertragung und eine archivierte Wiedergabe werden auf der Investor-Relation-Webseite des Unternehmens verfügbar sein.
Tenax Therapeutics (NASDAQ: TENX) ستشارك في مؤتمر Guggenheim للابتكار في الرعاية الصحية، الحدث السنوي الثاني في بوسطن من 10 إلى 12 نوفمبر 2025. عرض الشركة هو حوار بجانب المدفأة في 10 نوفمبر 2025 الساعة 4:00 مساءً بتوقيت شرق الولايات المتحدة، بمشاركة كريس جورْدانو، الرئيس التنفيذي، وستيوارت ريتش، دكتور في الطب، المدير الطبي. ستكون هناك بث مباشر وإعادة عرض أرشيفية متاحة على صفحة العلاقات مع المستثمرين بالشركة.
- None.
- None.
CHAPEL HILL, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the Guggenheim 2nd Annual Healthcare Innovation Conference, which is taking place from November 10-12, 2025, in Boston, MA.
Details of presentation:
Format: Fireside chat
Participants: Chris Giordano, President & Chief Executive Officer, Stuart Rich, M.D., Chief Medical Officer
Date and Time: November 10, 2025, at 4:00 p.m. ET
The live and archived webcast of the presentation will be accessible from the Company’s investor relations webpage.
About Tenax Therapeutics
Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. The Company owns global rights to develop and commercialize levosimendan, which it is developing for the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension globally, for which no product has been approved to date. For more information, visit tenaxthera.com. Tenax Therapeutics’ common stock is listed on The Nasdaq Stock Market LLC under the symbol “TENX”.
Contact:
Investor and Media:
Argot Partners
tenax@argotpartners.com
FAQ
When and where will Tenax Therapeutics (TENX) present at the Guggenheim Healthcare Innovation Conference?
Who will participate in the Tenax (TENX) presentation on November 10, 2025?
How can investors watch Tenax Therapeutics (TENX) at the Guggenheim conference?
What is the format of Tenax Therapeutics' (TENX) presentation at the Guggenheim conference?
Will Tenax (TENX) share clinical or financial data during the November 10, 2025 presentation?
Where can I find the archived webcast of Tenax Therapeutics' (TENX) Guggenheim presentation after November 10, 2025?
